Relief in sight for Migraine sufferers?

Relief in sight for Migraine sufferers?

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine!

Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. 

The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.

The most common treatment for OIC involves stool softeners, bulk laxatives, and bowel stimulants, but despite aggressive use of laxatives patients with OIC find constipation persists, with only half achieving the desired results with standard therapy. Chronic use of bowel stimulants is also controversial as prolonged use can lead to dependency on the stimulant to produce laxation .

Naloxone has been described as the “gold standard” opioid antagonist, used to reverse the effects of opioids 

An international double-blind randomized placebo controlled study evaluated the safety and efficacy of four doses of a new sustained release naloxone capsule to treat Opioid Induced Constipation (OIC).

This Phase II study has shown that using a new sustained release formulation to deliver oral naloxone to the colon allows successful treatment of OIC without comprising the desired opioid effects.